TVGN - Tevogen Bio Holdings Inc. Debt to Book Capitalization Ratio

Corporate company logo of Tevogen Bio Holdings (TVGN)

Tevogen Bio Holdings (TVGN) minimizes medical risks by developing methods to enhance immune defense for combating cancer and viruses. Successful trial phases of T-cell products and potential licensing deals are driving business growth. A unique software for developing non-rejection therapies and strong patent protection provide a technological advantage. The current indicator is 0.00, and the asset's market dynamics on GURU.Markets are available below.

tevogen.com (TVGN) - Debts to Book Value from 02/21/2024 to 10/29/2026

Summary analytical data breakdowns for Tevogen Bio Holdings Inc. (TVGN)

- price and consensus price forecast:
Stock Quotes Tevogen Bio Holdings|TVGN - Analyst Consensus Forecast
- market capitalization data:
Market Value Tevogen Bio Inc.|TVGN - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Tevogen Bio|TVGN - Total Stockholders' Equity|Market Cap to Net Assets Ratio tevogen.com|TVGN - Aggregate Business Assets
- debt and liquidity data:
Total Debt to Capital Tevogen Bio Holdings|TVGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Tevogen Bio Holdings, Inc.|TVGN - Company Debts|Debt to Book Capitalization Ratio Tevogen Bio Inc.|TVGN - Long-Term Debt|Company Short-Term Debts Tevogen Bio
Summary company analytics:Tevogen Bio Holdings - TVGN
Flagship merchandise of Tevogen Bio Inc.

To identify a fundamental support level for Tevogen Bio Holdings (TVGN) equity, it is essential to correlate the value of the ExCITE platform patents with the debt load under strict FDA oversight. By analyzing the company's debt-to-book capitalization ratio on GURU.Markets, an investor can determine the ratio of total liabilities to book value, enabling an assessment of default risk and the asset's financial stability in the face of regulatory challenges.

Competitors of Tevogen Bio Holdings

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Debts to Book Value Xenon Corp|Viking Therapeutics (VKTX) - Debt to Book Value|Debt to Book Capital supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value Denali DNLI|Debt to Book Value Harmony Pharma HRMY|Biohaven Corp - Debt to Book Capitalization Ratio|AMLX (Amylyx Pharmaceuticals) - Debt to Book Capitalization Ratio|TRVI - Debts to Book Value|Debts to Book Capitalization PRAX (Praxis Precision Medicines, Inc.)|Anavex (AVXL) - Debt to Net Assets|Debts to Book Capitalization CBLL (CeriBell Corp)|Debts to Book Value PRTA|Debt to Book Capitalization Ratio Alector, Inc. ALEC|Debt to Book Value Ratio annexonbio.com ANNX|Debt to Book Value Omeros|Debt to Net Assets Ratio Neurogene Inc NGNE|ACIU - Debts to Book Capitalization|VYGR - Debt to Book Capitalization Ratio|Neumora Therapeutics - Debts to Book Capitalization|SCLX (scilexholding.com) - Debts to Net Assets|Debt to Book Capitalization Ratio ACOG (Alpha Cognition Inc)|Debts to Book Value Cognition Therapeutics Inc. (CGTX)|Inhibikase (IKT) - Debt to Book Value|Debt to Net Assets Ratio Cassava Pharma (SAVA)|Debts to Book Capitalization Assertio|Coya Therapeutics Inc - Debt to Net Assets Ratio|VTGN (VistaGen Therapeutics Inc) - Debt to Book Capitalization Ratio|OVID: Debts to Book Value|Acumen Pharma (ABOS) - Debt to Book Capitalization Ratio|CervoMed Corporation (CRVO) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Alterity Therapeutics Ltd. (ATHE)|Debt to Book Value Ratio Clene Nanomedicine|PEPG (PepGen Inc.) - Debts to Book Capitalization|Debts to Net Assets JUNS (Jupiter Neurosciences, Inc.)|RLMD - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Annovis Bio Corporation ANVS|Debts to Book Capitalization GRCE|AIFF: Debt to Net Assets|anewmeds.com - Debt to Book Capitalization Ratio|Debts to Net Assets NeuroSense Therapeutics Ltd.|Reviva Pharmaceuticals Holdings (RVPH) - Debt to Book Value|Debt to Book Capital MetaVia, Inc. (MTVA)|Debt to Book Value NeurAxis, Inc. (NRXS)|Debt to Book Capitalization Ratio heliusmedical.com (HSDT)|PASG (Passage Bio) - Debts to Book Capitalization|Neuphoria Therapeutics, Inc. - Debt to Net Assets|Minerva Neurosciences Corp (NERV) - Debt to Book Capitalization Ratio|ATHA: Debt to Book Value Ratio|Debt to Book Capitalization Ratio Addex Therapeutics|Alzamend Neuro (ALZN) - Debt to Book Value Ratio|Debts to Book Capitalization CYCN (Cyclerion Therapeutics Inc.)|Debts to Book Value Protagenic (PTIX)|Debt to Book Value KTTA|Debts to Book Capitalization CRGT (cortigent.com)|Debt to Book Capitalization Ratio Avenue Therapeutics|brainstorm-cell.com - Debt to Net Assets Ratio|CARA (Cara Therapeutics) - Debt to Book Capitalization Ratio|Chromocell Therapeutics Corp (CHRO) - Debts to Book Value|ELYM - Debt to Book Value|Intra-Cellular Therapies, Inc. (ITCI) - Debt to Book Capital|Debts to Book Capitalization LBPH (Longboard Pharmaceuticals)|Debts to Book Value marinuspharma.com (MRNS)|Debt to Book Value NKGen Biotech (NKGN)|Debt to Book Capitalization Ratio NRBO (NeuroBo Pharmaceuticals Inc)|SAGE: Debt to Book Capitalization Ratio|Debts to Book Value Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN|VIGL - Debt to Net Assets|Debts to Book Capitalization WENA|CERE (Cerevel Therapeutics Inc) - Debts to Book Value